Autopsy report · NCT04963413
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
Cause of deathFunding or business
“Terminated by mutual agreement by sponsor and institution.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 1 year 8 months before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- University of Florida
- Sponsor type
- University, hospital or other
- Conditions
- Glioblastoma
- Interventions
- Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
- Participants
- 6
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache
“Terminated at the request of the financial sponsor.” - A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
“Terminated by Sponsor” - Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
“Terminated due to the sponsor's decision.” - Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
“Terminated by previous Sponsor decision” - RibFix Advantage™ Post-Market Follow-Up
“Sponsor Terminated”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.